Sanofi (SNY): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Sanofi ( SNY) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.1%. By the end of trading, Sanofi fell $1.56 (-3.0%) to $50.19 on heavy volume. Throughout the day, 5,983,655 shares of Sanofi exchanged hands as compared to its average daily volume of 1,288,200 shares. The stock ranged in price between $50.19-$51.35 after having opened the day at $51.23 as compared to the previous trading day's close of $51.75. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 42.7%, Stemline Therapeutics ( STML), down 9.0%, Aoxing Pharmaceutical Company ( AXN), down 8.6% and Agios Pharmaceuticals ( AGIO), down 7.4%.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $137.5 billion and is part of the health care sector. Shares are up 9.5% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Sanofi a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, Incyte ( INCY), up 33.5%, Inovio Pharmaceuticals ( INO), up 32.3%, GW Pharmaceuticals PLC ADR ( GWPH), up 20.3% and Oxygen Biotherapeutics ( OXBT), up 8.9% , were all gainers within the drugs industry with Gilead ( GILD) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Biotech Mailbag: Buy Dip in T2 Biosystems?

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

Sanofi Has Good Potential Upside

European Pharma Companies Slip on MS Pricing Probe